S-1: Livento Group Files for Resale of 83.3 Million Shares Amid Equity Line Financing

Livento Group, Inc. has filed a registration statement for the potential resale of up to 83,333,333 shares of its common stock by selling stockholders, including shares issuable under an Equity Line Purchase Agreement and upon exercise of warrants.

Summary

• Livento Group, Inc. has filed a Form S-1 registration statement for the resale of up to 83,333,333 shares of its common stock.
• The shares include 55,555,556 shares issuable under an Equity Line Purchase Agreement with an adjusted price of $0.009 per share and 27,777,778 shares issuable upon exercise of warrants issued to Alumni Capital LP.
• The exercise price per warrant share is calculated by dividing $15,000,000 by the total number of outstanding shares of common stock as of the exercise date.
• The selling stockholders may offer and sell the shares from time to time at prevailing market prices or negotiated prices.
• Livento Group will not receive any proceeds from the sale of these shares by the selling stockholders.
• The company's common stock is listed on the OTCMarkets under the symbol NUGN, with the last sale price on February 12, 2024, at $0.009.
• The company has two distinct operations, namely; BOXO a film development operation, Robotics primarily consisting of ELISE a propriety Artificial Intelligence Software product (ELISE or AI Software).
• BOXO plans to produce up to 6 movies and 12 television productions during 2024 and increase this number based on the success of this prospectus in raising capital investment.
• The Equity Line Purchase Agreement allows the Company to sell up to $500,000 of shares of the Company's common stock until December 31, 2025.
• The purchase price for the shares will be 90% of the volume-weighted average price (VWAP) of the common stock on the Nasdaq Stock Market for the five business days prior to a closing.
• The company is issuing to the Equity Line Investor a five year warrant entitling the Investor to purchase up to $250,000 of shares of common stock at an exercise price per warrant share calculated by dividing $15,000,000 by the total number of outstanding shares of common stock as of the Exercise Date.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's potential for growth in the film and AI sectors, the company's reliance on equity financing and history of losses raise concerns. The equity line provides some financial flexibility, but also dilutes existing shareholders.

Positives

• The Equity Line Purchase Agreement provides a potential source of funding for the company, up to $500,000 until December 31, 2025.
• BOXO plans to produce up to 6 movies and 12 television productions during 2024, potentially increasing revenue.
• The company has two distinct operations, namely; BOXO a film development operation, Robotics primarily consisting of ELISE a propriety Artificial Intelligence Software product (ELISE or AI Software).

Negatives

• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The company has realized significant operating losses to date and expects to incur losses in the future.
• The Company has limited capitalization and a lack of working capital and as a result is dependent on raising funds to grow and expand its business.

Risks

• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company has realized significant operating losses to date and expects to incur losses in the future.
• The company has limited capitalization and a lack of working capital and as a result is dependent on raising funds to grow and expand its business.
• The company is dependent on the sale of its securities to fund its operations.
• The profitability of attempted project acquisitions and media development is uncertain.
• There is a limited established trading market for our common stock and if a trading market does not develop, purchasers of our securities may have difficulty selling their securities.
• We may, in the future, issue additional Shares of common stock, which would reduce investors percent of ownership and may dilute our share value.

Future Outlook

BOXO plans to produce up to 6 movies and 12 television productions during 2024 and increase this number based on the success of this prospectus in raising capital investment.

Industry Context

The document notes the growing demand for content to fill cinemas after COVID-19 and the expansion of online content distributors, indicating a shift in the entertainment industry towards streaming and digital content.

Stakeholder Impact

• Existing shareholders may experience dilution due to the potential issuance of new shares.
• The company's ability to execute its business plan and generate revenue will impact its employees and consultants.
• The success of BOXO's film projects will affect the company's relationships with distributors and investors.

Next Steps

• The selling stockholders may offer and sell the shares from time to time at prevailing market prices or negotiated prices.
• The company will use the proceeds of the condominium sales to fund the activity and operations of BOXO.
• BOXO plans to produce up to 6 movies and 12 television productions during 2024 and increase this number based on the success of this prospectus in raising capital investment.

Key Dates

Keywords

common stock, equity line, resale, warrants, financing, BOXO, ELISE, Livento Group